DIVA Laboratories Ltd Cash Flow Conversion Efficiency
DIVA Laboratories Ltd cash flow conversion efficiency. Based on the latest financial reports, DIVA Laboratories Ltd (4153) has a cash flow conversion efficiency ratio of -0.018x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-16.94 Million ≈ $-533.61K USD) by net assets (NT$936.07 Million ≈ $29.49 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of DIVA Laboratories Ltd (2017–2025)
Cash flow conversion efficiency of DIVA Laboratories Ltd from 2017 to 2025. This chart illustrates how DIVA Laboratories Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View DIVA Laboratories Ltd (4153) stock price for real-time trading data and today's change.
DIVA Laboratories Ltd Cash Flow Conversion Ratio Explained
DIVA Laboratories Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
DIVA Laboratories Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of DIVA Laboratories Ltd ranked by their cash flow conversion efficiency. Also see 4153 stock market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Cintac
SN:CINTAC
|
0.119x |
|
Mandom Indonesia Tbk
JK:TCID
|
0.032x |
|
Cassava Sciences Inc
NASDAQ:SAVA
|
-0.130x |
|
Seresco S.A.
MC:SCO
|
0.137x |
|
Mercor S.A.
WAR:MCR
|
-0.262x |
|
JCBNext Berhad Bhd
KLSE:0058
|
0.011x |
|
Biome Australia Ltd
AU:BIO
|
0.344x |
|
Fanhua Inc.
NASDAQ:AIFU
|
0.117x |
Annual Cash Flow Conversion Efficiency for DIVA Laboratories Ltd (2017–2025)
The table below shows the annual cash flow conversion efficiency of DIVA Laboratories Ltd from 2017 to 2025. Review DIVA Laboratories Ltd (4153) free cash flow to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | NT$1.03 Billion ≈ $32.42 Million |
NT$20.77 Million ≈ $654.34K |
0.020x | -82.70% |
| 2024-12-31 | NT$1.06 Billion ≈ $33.25 Million |
NT$123.14 Million ≈ $3.88 Million |
0.117x | -52.36% |
| 2023-12-31 | NT$1.03 Billion ≈ $32.54 Million |
NT$252.91 Million ≈ $7.97 Million |
0.245x | +240.01% |
| 2022-12-31 | NT$1.02 Billion ≈ $32.02 Million |
NT$73.19 Million ≈ $2.31 Million |
0.072x | +723.74% |
| 2021-12-31 | NT$986.42 Million ≈ $31.08 Million |
NT$-11.39 Million ≈ $-358.85K |
-0.012x | +31.40% |
| 2020-12-31 | NT$988.89 Million ≈ $31.16 Million |
NT$-16.64 Million ≈ $-524.38K |
-0.017x | -136.22% |
| 2019-12-31 | NT$1.13 Billion ≈ $35.70 Million |
NT$52.66 Million ≈ $1.66 Million |
0.046x | -36.04% |
| 2018-12-31 | NT$1.18 Billion ≈ $37.30 Million |
NT$86.02 Million ≈ $2.71 Million |
0.073x | +41.41% |
| 2017-12-31 | NT$806.75 Million ≈ $25.42 Million |
NT$41.45 Million ≈ $1.31 Million |
0.051x | -- |
About DIVA Laboratories Ltd
DIVA Laboratories, Ltd. engages in the research, development, manufacture, and sale of medical devices and computer peripherals worldwide. The company provides endo/surgical displays for hybrid and other types of OR applications; color and mono displays for radiology applications; and touch and embedded display, as well as industrial displays. DIVA Laboratories, Ltd. was founded in 1984 and is he… Read more